Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia
NCT03850964Phase 3Completed
- Sponsor
- Cure HHT
- Start
- May 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pazopanib in hereditary hemorrhagic telangiectasia (HHT), epistaxis, anemia, sponsored by Cure HHT. Started May 2023; status: completed.
02
Drugs
pazopanib
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)epistaxisanemia
Beyond the preview
Go deeper on NCT03850964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850964.